Clinical trial · Interventional
Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney Cancer
TREATMENT OF METASTATIC RENAL CELL CARCINOMA WITH LOW-DOSE INTRAVENOUS RECOMBINANT INTERLEUKIN-2
NCT00002846CI-TRIAL-00013197unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. PURPOSE: Phase II trial to study the effectiveness of low-dose interleukin-2 in treating patients with metastatic or recurrent kidney cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| aldesleukin | Biological | Aldesleukin | ALIAS |
| conventional surgery | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed renal cell carcinoma (RCC) that is metastatic or recurrent * No central nervous system or major nerve involvement * No more than 25% estimated hepatic replacement by tumor on CT or MRI * Measurable disease required PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Karnofsky 80%-100% Life expectancy: * Greater than 3 months Hematopoietic: * Platelet count at least 80,000/mm3 Hepatic: * Bilirubin normal * AST and ALT no greater than 3 times normal Renal: * Creatinine normal Cardiovascular: * Stress cardiac exam normal (exam performed in patients aged 50 and older and in those with potential cardiac disease suggested by history, physical exam, or EKG) Pulmonary: * FEV1 and VC greater than 65% of predicted (tests performed in patients with significant smoking history and in those with potential pulmonary disease suggested by history, physical exam, or x-ray) Other: * No sites of ongoing bleeding * No HIV antibody or AIDS * No hepatitis B antigen * No systemic infection * No requirement for steroids * No psychiatric disease that precludes informed consent or safe administration of immunotherapy * No second malignancy except: * Basal cell carcinoma * In situ cervical cancer * Other cancer provided all evaluable lesions are documented RCC * No pregnant or nursing women * Effective contraception required of fertile women PRIOR CONCURRENT THERAPY: Biologic therapy * No prior interleukin-2 therapy Chemotherapy * Not specified Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified Other * At least 28 days since therapy for RCC
References
Publications (0)
Data not yet available
No reference posted for this study.